We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Stevens-Johnson Syndrome Associated With Long-Acting Sulfonamides

Oree M. Carroll, MD; Paul A. Bryan, MD; Robert J. Robinson, MD
JAMA. 1966;195(8):691-693. doi:10.1001/jama.1966.03100080131046.
Text Size: A A A
Published online


THE STEVENS-JOHNSON syndrome (erythema multiforme exudativum; Behçet syndrome)1 appears to be causally related to the use of the long-acting sulfonamides as well as other drugs and certain disease conditions.2,3 In an attempt to clarify this association and to delineate the scope of the problem, the Bureau of Medicine of the Food and Drug Administration has surveyed reports from the medical literature, reviewed adverse drug reaction data from other sources in the files of the FDA, and consulted various experts in the field. This communication is a summary of the data obtained and outlines FDA actions on the long-acting sulfonamides.

Background Considerations  The first long-acting sulfonamide was introduced to American medicine in 1957. At the present time, sulfamethoxypyridazine and sulfadimethoxine are in wide clinical use. These drugs require as little as one oral dose every 24 hours to maintain adequate therapeutic levels, thus differing markedly from the short-acting congeners.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.